On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.
Sponsored by Roche
Advertisement
Articles by Sponsored by Roche
Advertisement
Latest Updated Articles
ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLCPublished: May 30th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5